STAG3 cohesin complex component like 3 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored STAG3L3 profile across patient tissues and cancer cell-line models. STAG3L3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, STAG3L3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, STAG3L3 RNA expression shows 19,918 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, HNSC, and THYM as cancer lineages where STAG3L3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAG3L3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAG3L3 survival associations across molecular data types. STAG3L3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAG3L3 RNA expression–survival associations across cancer types. High STAG3L3 expression shows unfavorable associations in LGG, KIRC, UVM and COAD, but favorable associations in UCS and LAML. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for STAG3L3 RNA expression.
This table summarizes STAG3L3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for STAG3L3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAG3L3 shows higher tumor expression in HNSC, STAD, LIHC, BLCA, CHOL and COAD. The HNSC box plot shows higher STAG3L3 RNA expression in tumor versus normal tissue (log2 FC = +0.235, t-test p < 0.001).
This table shows molecular features associated with STAG3L3 in patient tissues and cancer cell lines. In patient samples, STAG3L3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, STAG3L3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
